Evidence library
Community Practices & Evidence
Explore what people report using, why they combine it, and how those claims compare with scientific research. Follow the source, understand the limits, and help shape better questions.
For healthcare professionals and the general public; public reading is free.
Editorial draft for review · scientific and translation review pending
Start here
Ten short guides for reading the profiles: how claims are labelled, how reported doses are handled and how experience becomes a research question.
- 01Understanding community practicesBegin with the question people bring, then follow the claim to its source.
- 02What each evidence label meansClassify the claim, not the popularity of the molecule.
- 03Stacks, mixtures and claims of synergyA useful comparison begins with composition, not a brand-like nickname.
- 04How we handle reported doses and cyclesNumbers can identify a claim without becoming a recommendation.
- 05Reading a peptide quality reportAsk what was measured, in which sample, and what remains unanswered.
- 06When someone says it workedRespect the experience and examine what could explain it.
- 07Source errors, corrections and retractionsScientific integrity includes changing the conclusion when the source changes.
- 08From experience to a research questionBetter data begin with a defined question and consistent follow-up.
- 09The proposed Community Observation ProgramA transparent development roadmap, with collection status visible.
- 10Reading future observational resultsAlways ask who is counted, who is missing and what was measured.
Explore reported practices
Each profile records what books and practice sources describe, not how common it is. Reported doses are never turned into recommendations.
These are reported aims, not established benefits or eligibility for a study.
24 of 24 profiles
- Topic: Recovery and tissue repairBPC-157RecoveryGut, infection and immune-related aimsPractitioner and community sources describe BPC-157 for tendon, muscle and gastrointestinal complaints, sometimes with TB-500 or other compounds. Accounts differ in route, duration and intended outcomes.3 claims · 4 references
- Topic: Growth hormone axisCJC-1295Variants with and without DAC are distinct compoundsRecoveryMetabolism and body compositionCognition, mood and sleepSources describe CJC products, often paired with ipamorelin, for sleep, body composition and recovery. “Without DAC” is a naming issue that must be resolved rather than treated as a minor variation.2 claims · 2 references
- Topic: Growth hormone axisIpamorelinMetabolism and body compositionIpamorelin appears in community GH-secretagogue combinations. Some sources present cycling and timing as established principles without direct comparisons.2 claims · 2 references
- Topic: Recovery and tissue repairTB-500RecoveryTB-500 is described for repair and in Wolverine-type combinations. Sources and sellers may use overlapping names for different materials.1 claim · 2 references
- Topic: Skin and pigmentationGHK-CuRecoverySkin, hair and pigmentationGHK-Cu is described for skin, hair and systemic repair and appears in Glow/KLOW mixtures. Topical and injected practices are often discussed together.1 claim · 1 reference
- Topic: Metabolism and body compositionAOD-9604Metabolism and body compositionAOD-9604 is promoted for fat loss and paired with GH-axis or metabolic products. One volume incorrectly equates an hCG-labeled fragment with AOD.2 claims · 1 reference
- Topic: Growth hormone axisTesamorelinMetabolism and body compositionCommunity guides extend visceral-fat findings to short athletic or body-composition cycles and sometimes suggest special diluents.1 claim · 1 reference
- Topic: Sexual healthBremelanotide / PT-141Sexual healthPT-141 is described for sexual desire and performance across broad populations, including uses outside the studied product indication.2 claims · 1 reference
- Topic: Skin and pigmentationMelanotan IISkin, hair and pigmentationCommunity sources describe pigmentation and tanning routines, sometimes with deliberate ultraviolet exposure. Unregulated nasal products are another route of exposure.1 claim · 3 references
- Topic: Gut and immune functionKPVSkin, hair and pigmentationGut, infection and immune-related aimsKPV appears in gut, skin and inflammation protocols, alone or with BPC-157 and LL-37. Sources often move between oral and injected use.2 claims · 2 references
- Topic: Gut and immune functionLL-37Gut, infection and immune-related aimsLL-37 is described for antimicrobial, biofilm and inflammatory aims, sometimes as a systemic component of a gut or immune combination.2 claims · 2 references
- Topic: Gut and immune functionThymosin α1Gut, infection and immune-related aimsPractitioner sources describe broad immune support and extrapolate between infections and other conditions.1 claim · 1 reference
- Topic: Brain, mood and sleepDSIPCognition, mood and sleepDSIP is promoted for deep sleep and is paired with Epitalon in some accounts. Some schedules imply reliable or chronic benefit.1 claim · 1 reference
- Topic: Brain, mood and sleepSemax / SelankTwo distinct peptides covered in one profile — not identicalCognition, mood and sleepSemax and Selank are described for focus, anxiety, stress and cognitive performance. They are different molecules even when discussed together.2 claims · 2 references
- Topic: Mitochondria and ageingMOTS-cMetabolism and body compositionEnergy and exerciseMOTS-c is described in exercise, insulin-sensitivity and metabolic combinations. Community injection cycles extend beyond what an endogenous measurement can establish.1 claim · 1 reference
- Topic: Mitochondria and ageingElamipretide / SS-31RecoveryEnergy and exerciseSS-31 is described for fatigue, athletic recovery and mitochondrial optimization, sometimes paired with metabolic compounds.1 claim · 2 references
- Topic: Mitochondria and ageingEpitalonCognition, mood and sleepAgeing-related claimsEpitalon appears in longevity and sleep-related cycles. Some accounts interpret telomerase or telomere findings as cellular rejuvenation.1 claim · 1 reference
- Topic: Mitochondria and ageingHumaninAgeing-related claimsHumanin is described in anti-aging and mitochondrial combinations with repeated systemic dosing claims.1 claim · 1 reference
- Topic: Metabolism and body composition5-amino-1MQNon-peptide compoundMetabolism and body composition5-amino-1MQ is included in peptide-oriented guides for fat loss and metabolic combinations, although it is a small molecule rather than a peptide.1 claim · 1 reference
- Topic: Brain, mood and sleepDihexaCognition, mood and sleepDihexa is described for cognitive enhancement using mechanistic arguments involving HGF/c-Met signaling.1 claim · 1 reference
- Topic: Emerging and investigationalPNC-27Cancer-related claims — investigationalPNC-27 appears in practitioner cancer-treatment discussions, including claims of selective tumor effects and aggressive numerical protocols.1 claim · 2 references
- Topic: Stacks and mixturesWolverineRecoveryWolverine commonly refers in these sources to BPC-157 with TB-500-related material. Reported compositions and schedules differ and may involve separate vials.1 claim · 3 references
- Topic: Stacks and mixturesGlow / KLOWRecoverySkin, hair and pigmentationGlow and KLOW are names for reported multicomponent mixtures involving BPC-157, TB-500-related material, GHK-Cu and sometimes KPV. Names do not fix the composition.3 claims · 3 references
- Topic: Stacks and mixturesMetabolic combinationsMetabolism and body compositionEnergy and exerciseGuides propose adding GH-axis products, MOTS-c, AOD-9604 or SS-31 to incretin-based treatment for fat loss, muscle preservation or energy.3 claims · 4 references
Original topic tags (e.g. growth hormone axis, stacks) stay on each card; they are not goals.
Research roadmap
From experience to better questions
Experience can help identify research questions. The proposed Community Observation Program would document independently occurring exposures through a defined protocol, consistent follow-up and transparent analysis. It is currently in design; health-data collection is not open.
This design program now has a separate registry with private participation and reviewed aggregate results; current collection and results status is shown on the registry pages.
- 01Document independently occurring exposures with a defined protocol
- 02Record unknowns and unchanged, worse or stopped outcomes
- 03State source confidence and a defined denominator
- 04Only later: study-specific analysis